>>"Xyotax did for the most part what we thought it was going to do, except it fell short on the primary endpoint."
James Bianco, March 2005.<<
Not good enough for these guys:
>>RADNOR, Pa., March 10 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin & Barroway, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Western District of Washington on behalf of all securities purchasers of Cell Therapeutics Inc., (Nasdaq: CTIC - News; "CTI" or the "Company") between June 7, 2004 and March 4, 2005, inclusive (the "Class Period").
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Schiffrin & Barroway, LLP (Marc A. Topaz, Esq. or Darren J. Check, Esq.) toll-free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbclasslaw.com.
The complaint charges CTI, Max Link, and James Bianco with violations of the Securities Exchange Act of 1934. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that contrary to the defendant's express and repeated representations the results of STELLAR 3 trial were not encouraging; (2) that XYOTAX failed to boost survival for non-small cell lung cancer: (3) that XYOTAX failed to show greater survival benefit than Taxol, the leading drug on the market; and (4) that based on the results of the trial the Company would not be able to begin pre-launch activities and to position itself to submit a new drug application for XYOTAX.
On March 7, 2005, prior to the opening of the market, CTI announced that a phase III study of XYOTAX in combination with carboplatin, known as STELLAR 3, missed its primary endpoint. News of this shocked the market. Shares fell $4.75 per share or 47.5 percent, on March 7, 2005, to close at $5.25 per share, on unusually high volume.
Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Schiffrin & Barroway, which prosecutes class actions in both state and federal courts throughout the country. Schiffrin & Barroway is a driving force behind corporate governance reform, and has recovered in excess of a billion dollars on behalf of institutional and high net worth individual investors. For more information about Schiffrin & Barroway, or to sign up to participate in this action online, please visit sbclasslaw.com <<
snip
Can't say I'm surprised. Though proving defendants knew what is alleged is going to be tough, since the results were blinded. I've been waiting for this to create the buying opportunity.
Cheers, Tuck |
